184 related articles for article (PubMed ID: 17264765)
21. Novel achiral titanocene anti-cancer drugs synthesised from bis-N,N-dimethylamino fulvene and lithiated heterocyclic compounds.
Pampillón C; Claffey J; Hogan M; Tacke M
Biometals; 2008 Apr; 21(2):197-204. PubMed ID: 17665139
[TBL] [Abstract][Full Text] [Related]
22. A new generation of anticancer drugs: mesoporous materials modified with titanocene complexes.
Pérez-Quintanilla D; Gómez-Ruiz S; Zizak Z; Sierra I; Prashar S; del Hierro I; Fajardo M; Juranić ZD; Kaluderović GN
Chemistry; 2009; 15(22):5588-97. PubMed ID: 19370742
[TBL] [Abstract][Full Text] [Related]
23. New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay.
Salmon SE; Meyskens FL; Alberts DS; Soehnlen B; Young L
Cancer Treat Rep; 1981; 65(1-2):1-12. PubMed ID: 7226159
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic studies of substituted titanocene and ansa-titanocene anticancer drugs.
Gómez-Ruiz S; Kaluderović GN; Prashar S; Polo-Cerón D; Fajardo M; Zizak Z; Sabo TJ; Juranić ZD
J Inorg Biochem; 2008 Aug; 102(8):1558-70. PubMed ID: 18353439
[TBL] [Abstract][Full Text] [Related]
25. Anticancer activity and mode of action of titanocene C.
Olszewski U; Claffey J; Hogan M; Tacke M; Zeillinger R; Bednarski PJ; Hamilton G
Invest New Drugs; 2011 Aug; 29(4):607-14. PubMed ID: 20162321
[TBL] [Abstract][Full Text] [Related]
26. [Tumor stem cell cultures on agar: 1st results].
Ludwig C; Ludwig R; Obrecht JP
Schweiz Med Wochenschr; 1981 Sep; 111(36):1313-8. PubMed ID: 7302535
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of the cytotoxicity of titanocene dichloride by aging in organic co-solvent.
Ravera M; Cassino C; Monti E; Gariboldi M; Osella D
J Inorg Biochem; 2005 Dec; 99(12):2264-9. PubMed ID: 16209887
[TBL] [Abstract][Full Text] [Related]
28. [Progress in experimental chemotherapy of colorectal cancer].
Scheithauer W
Acta Med Austriaca; 1987; 14(5):118-24. PubMed ID: 3439421
[TBL] [Abstract][Full Text] [Related]
29. Potentials and drawbacks of the human tumor stem cell assay.
Shoemaker RH; Wolpert-DeFilippes MK; Venditti JM
Behring Inst Mitt; 1984 May; (74):262-72. PubMed ID: 6477356
[TBL] [Abstract][Full Text] [Related]
30. In-vitro toxicity of Ukrain against human Ewing tumor cell lines.
Lanvers-Kaminsky C; Nolting DM; Köster J; Schröder A; Sandkötter J; Boos J
Anticancer Drugs; 2006 Oct; 17(9):1025-30. PubMed ID: 17001175
[TBL] [Abstract][Full Text] [Related]
31. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
32. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
33. A controlled release system of titanocene dichloride by electrospun fiber and its antitumor activity in vitro.
Chen P; Wu QS; Ding YP; Chu M; Huang ZM; Hu W
Eur J Pharm Biopharm; 2010 Nov; 76(3):413-20. PubMed ID: 20854905
[TBL] [Abstract][Full Text] [Related]
34. Tumor inhibition by titanocene complexes: influence upon two xenografted human lung carcinomas.
Köpf-Maier P
J Cancer Res Clin Oncol; 1987; 113(4):342-8. PubMed ID: 3036884
[TBL] [Abstract][Full Text] [Related]
35. Tumor inhibition by titanocene complexes: influence on xenografted human adenocarcinomas of the gastrointestinal tract.
Köpf-Maier P
Cancer Chemother Pharmacol; 1989; 23(4):225-30. PubMed ID: 2924380
[TBL] [Abstract][Full Text] [Related]
36. Titanocene dichloride--the first metallocene with cancerostatic activity.
Köpf H; Köpf-Maier P
Angew Chem Int Ed Engl; 1979 Jun; 18(6):477-8. PubMed ID: 111586
[No Abstract] [Full Text] [Related]
37. Synthesis, characterization and cytotoxic activity on breast cancer cells of new half-titanocene derivatives.
Sirignano E; Saturnino C; Botta A; Sinicropi MS; Caruso A; Pisano A; Lappano R; Maggiolini M; Longo P
Bioorg Med Chem Lett; 2013 Jun; 23(11):3458-62. PubMed ID: 23623493
[TBL] [Abstract][Full Text] [Related]
38. Bioorganometallic fulvene-derived titanocene anti-cancer drugs.
Strohfeldt K; Tacke M
Chem Soc Rev; 2008 Jun; 37(6):1174-87. PubMed ID: 18497930
[TBL] [Abstract][Full Text] [Related]
39. Determination of titanocene, a new drug with anticancer potential, and its metabolism in solution by capillary electrophoresis.
Wittrisch H; Schröer HP; Vogt J; Vogt C
Electrophoresis; 1998 Nov; 19(16-17):3012-7. PubMed ID: 9870405
[TBL] [Abstract][Full Text] [Related]
40. Activity of titanocene dihalides against a human colon carcinoma heterotransplanted to athymic mice.
Köpf-Maier P; Moormann A; Köpf H
Eur J Cancer Clin Oncol; 1985 Jul; 21(7):853-7. PubMed ID: 4043173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
